Editas Medicine, Inc. — FY2021 Form 10-K Summary
Business context and reporting period. Editas Medicine is a clinical-stage gene-editing company developing CRISPR-based medicines. This annual report covers the fiscal year ended December 31, 2021; it does not provide a standalone Q4 income statement. Its most advanced programs were EDIT-101 for LCA10 and EDIT-301 for sickle cell disease and transfusion-dependent beta-thalassemia (TDT). The company had no product-sales revenue.
Financial performance and position
| Metric | FY2021 / Dec. 31, 2021 | Prior comparable period |
|---|---|---|
| Collaboration and research revenue | $25.5 million | $90.7 million in FY2020 |
| Research and development expense | $142.5 million | $158.0 million in FY2020 |
| General and administrative expense | $76.2 million | $67.6 million in FY2020 |
| Operating loss | $193.1 million | $134.8 million in FY2020 |
| Net loss | $192.5 million; $2.85 per share | $116.0 million; $1.98 per share in FY2020 |
| Operating cash flow | $(163.8) million | $(179.8) million in FY2020 |
| Cash, cash equivalents and marketable securities | $619.9 million | $511.8 million at Dec. 31, 2020 |
| Total assets / total liabilities | $677.5 million / $123.8 million | $572.6 million / $179.0 million at Dec. 31, 2020 |
Revenue, margins and profitability: Revenue was collaboration-based, principally from Juno Therapeutics, rather than product sales. Product gross margins are not applicable; the filing provides no product-sales margin. The company remained unprofitable and expects continued losses.
Liquidity, debt and cash flow: Current assets were $507.3 million and current liabilities were $46.9 million. The balance sheet lists operating lease liabilities of $26.4 million in total; it does not report conventional borrowings outstanding at year-end. The company reported $29.1 million of future minimum operating lease payments, including $12.0 million due in 2022. Financing activities provided $282.1 million, principally from a public offering and option exercises. Management estimated existing cash, cash equivalents and marketable securities would fund operating and capital needs through 2023, subject to forecast risks.
Material changes versus FY2020
- Revenue fell $65.2 million, chiefly because FY2020 included revenue recognized upon termination of the Allergan collaboration and revenue from an out-license agreement; these items did not recur in FY2021. Juno-related revenue increased by $13.5 million.
- Net loss increased $76.5 million, or 66%. Lower operating expenses did not offset the sharp decline in collaboration revenue and lower other income.
- R&D expense declined $15.5 million, mainly due to lower license and sublicense fees and lower external development costs, partly offset by higher employee, stock-based compensation and facility costs.
- G&A expense rose $8.6 million. Stock-based compensation increased substantially, including expense related to accelerated vesting of certain awards upon the former CEO’s separation and new market- and performance-based awards.
- FY2020 other income included a $16.4 million realized gain from the sale of Beam Therapeutics shares; FY2021 had no comparable gain.
- The company raised approximately $249.5 million net from a 2021 public offering and issued shares to settle a $27.5 million success-payment note. Shares outstanding increased from 62.6 million to 68.4 million during 2021.
Outlook, developments and key risks
- EDIT-101: The company completed dosing of three adult dose cohorts in 2021. Preliminary results from the first six patients showed no reported dose-limiting toxicities or serious adverse events; two of three followed patients in the mid-dose cohort showed early efficacy signals. These early findings are not proof of efficacy. The company planned additional adult enrollment, pediatric dosing in 2022 and a clinical update in the second half of 2022.
- EDIT-301: The FDA had cleared the safety portion of the RUBY sickle cell trial, with first dosing expected in the first half of 2022 and initial results by year-end. A partial clinical hold requires the company to develop a potency assay before a registrational trial; the filing warns that if the hold is not lifted, the company may be unable to collect efficacy data needed to support approval. The FDA cleared the TDT trial in December 2021, with dosing expected in 2022.
- Other programs: Editas declared EDIT-103 for RHO-associated autosomal dominant retinitis pigmentosa and EDIT-202, an iPSC-derived NK-cell candidate for solid tumors, as development candidates in December 2021. EDIT-102 remained in lead optimization. The company planned to advance EDIT-202 preclinically and expected another ocular development candidate in 2022.
- Financial outlook: Management expected expenses to rise as clinical programs advance and stated it did not expect profitability in 2022 or the foreseeable future. Additional financing will likely be needed; equity financing could dilute shareholders, while collaborations or licensing could require surrendering valuable rights. A $300 million at-the-market facility was available, but no shares had been sold under it by the filing date.
- Principal risks: Clinical and regulatory uncertainty for novel gene-editing medicines; potential off-target edits and safety issues; the EDIT-301 partial hold and potency-assay requirement; reliance on third-party manufacturers and collaborators; competition and uncertain reimbursement; and significant CRISPR patent priority and validity disputes, including multiple U.S. interference proceedings and European patent oppositions. COVID-19 and changing variants could also disrupt trials, staffing or supply.
- Unusual items and controls: FY2021 included $43.4 million of stock-based compensation, up from $23.2 million in FY2020. The auditor issued unqualified opinions on the financial statements and internal control over financial reporting; management also concluded controls were effective.
Important facts for investors to verify
- Whether EDIT-101’s larger and longer-followed clinical dataset confirms a durable, clinically meaningful benefit and establishes registrational endpoints.
- Progress on the EDIT-301 potency assay and partial hold, and whether the program can generate the efficacy evidence needed for a future approval application.
- Actual cash burn, milestone and collaboration receipts, and whether the stated runway through 2023 remains achievable as development spending grows.
- Potential dilution from future equity financing, employee awards and the unused at-the-market facility.
- Developments in CRISPR patent disputes, licensing obligations and any resulting constraints, costs or changes to commercial rights.
- Whether new development candidates advance on the stated timelines and whether the company’s collaboration revenue can support operations without product sales.